The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies-Reference-Cited by-同舟云学术

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

Published:2018-03-23 Issue:6382 Volume:359 Page:1366-1370
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Zitvogel Laurence¹²³⁴^ORCID,Ma Yuting⁵⁶^ORCID,Raoult Didier⁷,Kroemer Guido⁸⁹¹⁰^ORCID,Gajewski Thomas F.¹¹^ORCID

Affiliation:

1. Gustave Roussy Cancer Campus (GRCC), Equipe Labellisée–Ligue Nationale contre le Cancer, Villejuif, France.

2. Institut National de la Santé et de la Recherche Medicale (INSERM) U1015, Villejuif, France.

3. Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

4. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.

5. Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, 100005 Beijing, China.

6. Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.

7. Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, Institut Hospitalo-Universitaire (IHU)–Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005 Marseille.

8. Centre de Recherche des Cordeliers, Université Paris Descartes, Sorbonne Paris Cité, Université Pierre et Marie Curie, Paris, France.

9. Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.

10. Equipe 11 Labellisée–Ligue Nationale Contre le Cancer, UMRS 1138, Paris, France.

11. Department of Pathology, Department of Medicine, and the Ben May Department of Cancer, University of Chicago, Chicago, IL 60615, USA.

Abstract

The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference74 articles.

1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

2. Elements of cancer immunity and the cancer–immune set point

3. Accounting for reciprocal host–microbiome interactions in experimental science

4. Role of the intestinal microbiome in health and disease: from correlation to causation

5. Revised Estimates for the Number of Human and Bacteria Cells in the Body

Cited by 497 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translational research in head and neck cancer: Molecular and immunological updates;Auris Nasus Larynx;2024-04

2. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer;Frontiers in Immunology;2024-02-01

3. The critical role of tumor microbiome in cancer immunotherapy;Cancer Biology & Therapy;2024-01-19

4. Nourishing the gut: the impact of diet on host–gut microbiota interaction;Current Opinion in Clinical Nutrition & Metabolic Care;2024-01-18

5. A dynamic atlas of immunocyte migration from the gut;Science Immunology;2024-01-12